A Phase Ib Trial of PX-12 Administered as a 72-Hour Infusion Every 21 Days in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer That is Refractory to Standard Treatment.
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
At a glance
- Drugs PX 12 (Primary)
- Indications Cancer metastases; Lymphoma
- Focus Adverse reactions
- 05 Feb 2010 Actual end date (Aug 2009) and actual number of patients (14) added as reported by ClinicalTrials.gov.
- 11 Jun 2009 Status changed from active, no longer recruiting to completed. Final results have been presented.
- 30 May 2009 Final results have been presented at American Society of Clinical Oncology (ASCO) Annual Meeting, according to an Oncothyreon media release.